PBLA (Panbela Therapeutics) Operating Margin %: 0.00% (As of Sep. 2024)


What is Panbela Therapeutics Operating Margin %?

Panbela Therapeutics PBLA +2,400.00% Operating Margin % is 0.00% as of Sep. 2024.

Operating Margin % is calculated as Operating Income divided by its Revenue. Panbela Therapeutics's Operating Income for the three months ended in Sep. 2024 was $-7.17 Mil. Panbela Therapeutics's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, Panbela Therapeutics's Operating Margin % for the quarter that ended in Sep. 2024 was 0.00%.

The historical rank and industry rank for Panbela Therapeutics's Operating Margin % or its related term are showing as below:


PBLA's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -86.89
* Ranked among companies with meaningful Operating Margin % only.

Panbela Therapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Panbela Therapeutics's Operating Income for the three months ended in Sep. 2024 was $-7.17 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2024 was $-29.04 Mil.


Panbela Therapeutics  (OTCPK:PBLA) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Panbela Therapeutics Operating Margin % Related Terms


Panbela Therapeutics Operating Margin % Historical Data

* Premium members only.

The historical data trend for Panbela Therapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Panbela Therapeutics Operating Margin % Chart

Panbela Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Panbela Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PBLA vs VINC, OMGAQ, ENDV: Operating Margin % Comparison

For the Biotechnology subindustry, Panbela Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Panbela Therapeutics Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Panbela Therapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Panbela Therapeutics's Operating Margin % falls into.



Panbela Therapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Panbela Therapeutics's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-25.647 / 0
= %

Panbela Therapeutics's Operating Margin % for the quarter that ended in Sep. 2024 is calculated as

Operating Margin %=Operating Income (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=-7.165 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 0.00% mean?
Panbela Therapeutics (PBLA) has a Operating Margin % of 0.00% as of Sep. 2024. Operating margin is the ratio of total operating income to net sales. View historical data on Panbela Therapeutics and its competitors.
Is Panbela Therapeutics' Operating Margin % too high?
Panbela Therapeutics' current Operating Margin % is 0.00%.
How does Panbela Therapeutics' Operating Margin % compare to VINC and OMGAQ?
Panbela Therapeutics' Operating Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Panbela Therapeutics and its competitors. Panbela Therapeutics's current Operating Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panbela Therapeutics stock overvalued right now?
Panbela Therapeutics (PBLA) has a current Operating Margin % of 0.00%. The current Operating Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Panbela Therapeutics (PBLA), the current Operating Margin % is 0.00% as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Panbela Therapeutics Business Description

Address 712 Vista Boulevard, Suite 305, Waconia, MN, USA, 55387
Panbela Therapeutics Inc is a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The Company's pipeline assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X), which provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity.